Ozempic, Wegovy list prices to be slashed by up to 50%

Published: Thursday, February 26, 2026 at 5:25 pm

Novo Nordisk to Slash Prices of Ozempic and Wegovy

Novo Nordisk, the pharmaceutical giant, has announced significant price reductions for its popular weight loss and diabetes medications, Ozempic and Wegovy. Starting January 1, 2027, the list prices for both drugs will be cut by up to 50%.

Wegovy, currently priced at $1,349 per month, will be reduced to $675. Ozempic, currently listed at $1,028 for a one-month supply, will also be priced at $675. This represents a reduction of approximately 50% for Wegovy and 35% for Ozempic.

The company stated that the price cuts are intended to improve affordability for patients who receive these medications through their health insurance plans. Some insurance plans base coverage and out-of-pocket expenses on the list price of medications. The price reductions are expected to be particularly beneficial for individuals with high-deductible health plans or co-insurance benefit designs.

This announcement follows previous price cuts implemented by Novo Nordisk. Last year, the company reduced the price of Ozempic and Wegovy to $349 per month for those paying full price without insurance. Additionally, the drugs are now more affordable for those on Medicare due to a deal with the government.

The announcement of the price cuts came shortly after the release of a study indicating that Novo Nordisk's next-generation weight loss drug, CagriSema, did not perform as well as Eli Lilly's Zepbound and Mounjaro in a clinical trial.

BNN's Perspective:

While the price cuts are undoubtedly a positive development for patients, it's important to consider the broader implications. The pharmaceutical industry is complex, and these decisions are likely driven by a combination of factors, including market competition and the need to maintain profitability. The long-term impact on access to these medications and the overall healthcare landscape remains to be seen.

Keywords: Ozempic, Wegovy, Novo Nordisk, price cuts, weight loss drugs, diabetes drugs, medication affordability, health insurance, high-deductible health plans, co-insurance, CagriSema, Eli Lilly, Zepbound, Mounjaro, Medicare

Full Story